| Name | Title | Contact Details |
|---|
Providing real-time asset tracking in any environment, with applications in manufacturing, defense, energy, inventory management, logistics, and security. WISERs ultra-wideband (UWB) system operates without line-of-sight and registers asset locations within inches in most cases.
Established over 100 years ago, NSK (Nippon Seiko Kabushiki Kaisha) is a Japanese-listed company that has evolved from a regional ball bearing supplier to a roller bearing specialist and automotive supplier with a global market presence. Today, NSK employs more than 31.500 employees in 29 countries. This result has been driven by ever-increasing investment in research & development, enabling the company to continuously improve the quality of its products and services. This investment supports NSKs objective of "No. 1 in Total Quality". In addition to a complete rolling bearing portfolio, NSK develops and manufactures precision components and mechatronic products, as well as systems and components for the automotive industry, including wheel bearing units and electric power-steering systems. www.nskamericas.com www.nskeurope.com www.nsk.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Modern management software for gyms, martial arts schools, yoga studios and membership clubs.
PartnersFinancial is a member-centric network of successful, independent peers working together to drive life insurance sales. We harness, enable and spread the knowledge, insights and expertise of over 150 life insurance and diversified firms across the country. Our expertise is matched only by our personal commitment to each others and our clients goals.